Taysha Gene Therapies Inc...

NASDAQ: TSHA · Real-Time Price · USD
2.79
0.01 (0.36%)
At close: Jun 04, 2025, 3:59 PM
2.87
2.87%
After-hours: Jun 04, 2025, 07:58 PM EDT

Company Description

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.

It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

The company was incorporated in 2019 and is based in Dallas, Texas.

Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc. logo
Country United States
IPO Date Sep 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 73
CEO Sean P. Nolan

Contact Details

Address:
3000 Pegasus Park Drive
Dallas, Texas
United States
Website https://www.tayshagtx.com

Stock Details

Ticker Symbol TSHA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001806310
CUSIP Number 877619106
ISIN Number US8776191061
Employer ID 84-3199512
SIC Code 2836

Key Executives

Name Position
Sean P. Nolan Chief Executive Officer & Chairman
Kamran Alam CPA, M.B.A. Chief Financial Officer & Corporate Secretary
Tracy M. Porter SPHR Chief People Officer
Berge Minassian M.D. Chief Medical Advisor of UT Southwestern Gene Therapy Program
Dr. Steven Gray Ph.D. Chief Scientific Advisor of UT Southwestern Gene Therapy Program
Dr. Sukumar Nagendran M.D. President, Head of Research & Development and Director
Emily McGinnis M.P.H. Chief Patient & External Affairs Officer
Frederick Porter Ph.D. Chief of Staff & Technical Operations Officer
Hayleigh Collins Director of Corporate Communications & Investor Relations
Sean McAuliffe Chief Business Officer

Latest SEC Filings

Date Type Title
Jun 03, 2025 SCHEDULE 13D/A [Amend] Filing
Jun 03, 2025 4 Filing
Jun 03, 2025 8-K Current Report
May 29, 2025 8-K Current Report
May 29, 2025 424B5 Filing
May 29, 2025 8-K/A [Amend] Current Report
May 28, 2025 424B5 Filing
May 28, 2025 8-K Current Report
May 15, 2025 10-Q Quarterly Report
May 15, 2025 8-K Current Report